⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

September 16, 2024

Supplementary Figure 3 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer

Yonghong Chen Catherine R. Dufour Lingwei Han Ting Li Hui Xia Vincent Giguère

View at Publisher

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Supplementary Figure 3. SKP2 is an E3 ligase for HOXB13.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2024) studied this question.

synapsesocial.com/papers/68e586c1b6db6435875237aa https://doi.org/10.1158/1541-7786.27035293

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Supplementary Figure 3 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024
2Supplementary Figure 2 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024
3Supplementary Figure 2 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024
4Supplementary Figure 5 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024
5Supplementary Figure 5 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024

Supplementary Figure 1 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024
Supplementary Figure 1 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024
Supplementary Figure 4 from Hierarchical phosphorylation of HOXB13 by mTOR dictates its activity and oncogenic function in prostate cancer2024